Spark takes a beating as hemophilia safety setbacks torpedo stock, burnish rival BioMarin
Every tiny gene therapy study run by a public biotech looking to make a breakthrough in curing a disease has two critical features. There’s the regulatory side, where FDA and EMA insiders need to be persuaded of their potential. And there’s the market side, where a host of analysts — real and self-appointed social media mavens — are ready to jump on any adverse event as a sign of impending defeat.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
